Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

NIH 3OTHER 1NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 12Thoracic 9Gynecologic 9Other hematologic neoplasm 6Lymphoid 5Genitourinary 5CNS 5Sarcoma 4Gastrointestinal 4Breast 4Plasma cell 2Other solid neoplasm 2Other 2Myeloid 1Dermatologic 1

Conditions

Neutropenia 1Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1Leukemia 1Drug-Related Side Effects and Adverse Reactions 1Blast Crisis 1

Interventions

Cyclophosphamide 229fludarabine phosphate 206fludarabine 163Busulfan 150Mycophenolic Acid 135Tacrolimus 133Whole-Body Irradiation 132Peripheral Blood Stem Cell Transplantation 121Cytarabine 101Azacitidine 100Antilymphocyte Serum 98Melphalan 96Cyclosporine 96Methotrexate 87Imatinib Mesylate 87Filgrastim 85Decitabine 66Granulocyte Colony-Stimulating Factor 60Thiotepa 57venetoclax 53Stem Cell Transplantation 53thymoglobulin 51Radiotherapy 49Cord Blood Stem Cell Transplantation 42nilotinib 40Clofarabine 38Dasatinib 37Methylprednisolone 36ruxolitinib 35Etoposide 35

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Amifostine × Myeloid × Clear all
NCT00003407 2023-02-02

Amifostine & High-Dose Combination Chemotherapy in Treating Patients With Acute ML or CML

Rush University Medical Center

Phase 2 Withdrawn
MyeloidOther hematologic neoplasm

Blast Crisis, Leukemia, Myelodysplastic Syndromes, Neutropenia, Leukemia, Myeloid, Acute, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡